Baris Deniz

526 total citations
25 papers, 412 citations indexed

About

Baris Deniz is a scholar working on Epidemiology, Oncology and Hepatology. According to data from OpenAlex, Baris Deniz has authored 25 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 9 papers in Oncology and 8 papers in Hepatology. Recurrent topics in Baris Deniz's work include Hepatitis C virus research (8 papers), Liver Disease Diagnosis and Treatment (5 papers) and Multiple Sclerosis Research Studies (4 papers). Baris Deniz is often cited by papers focused on Hepatitis C virus research (8 papers), Liver Disease Diagnosis and Treatment (5 papers) and Multiple Sclerosis Research Studies (4 papers). Baris Deniz collaborates with scholars based in United States, United Kingdom and Türkiye. Baris Deniz's co-authors include Diana Brixner, Christopher A. Hane, Lisa J. McGarry, Joseph Biskupiak, Carrie McAdam‐Marx, Sujata P. Sarda, Jaime Rubin, Michael Hutchinson, Mohd Kashif Siddiqui and Joseph Menzin and has published in prestigious journals such as Blood, PLoS ONE and American Journal of Public Health.

In The Last Decade

Baris Deniz

24 papers receiving 399 citations

Peers

Baris Deniz
Farhad Peerani Canada
Angie Price United States
Hesham Elghazaly Egypt
Jean‐Charles Ryff Switzerland
V. Iodice Italy
Carmen Monica Preda Romania
G Bardazzi Italy
M.-S. Dai Taiwan
Lotte C. Dinesen United Kingdom
Faleh Z. Al-Faleh Saudi Arabia
Farhad Peerani Canada
Baris Deniz
Citations per year, relative to Baris Deniz Baris Deniz (= 1×) peers Farhad Peerani

Countries citing papers authored by Baris Deniz

Since Specialization
Citations

This map shows the geographic impact of Baris Deniz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baris Deniz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baris Deniz more than expected).

Fields of papers citing papers by Baris Deniz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baris Deniz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baris Deniz. The network helps show where Baris Deniz may publish in the future.

Co-authorship network of co-authors of Baris Deniz

This figure shows the co-authorship network connecting the top 25 collaborators of Baris Deniz. A scholar is included among the top collaborators of Baris Deniz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baris Deniz. Baris Deniz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abraham, Ivo, Amit Goyal, Baris Deniz, et al.. (2022). Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States. Journal of Managed Care & Specialty Pharmacy. 28(4). 435–448. 7 indexed citations
2.
Deniz, Baris, Shuo Yang, Arman Altincatal, et al.. (2019). Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS ONE. 14(8). e0215761–e0215761. 15 indexed citations
3.
Deniz, Baris, Arman Altincatal, Sumati Rao, et al.. (2018). Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS ONE. 13(8). e0203406–e0203406. 1 indexed citations
4.
Vicente, Colin, et al.. (2016). The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Journal of Medical Economics. 19(7). 718–727. 20 indexed citations
5.
Brogan, Anita J., Sandra E. Talbird, James R. Thompson, et al.. (2014). Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C. PLoS ONE. 9(3). e90295–e90295. 19 indexed citations
6.
Hutchinson, Michael, Robert J. Fox, Eva Havrdová, et al.. (2013). Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research and Opinion. 30(4). 613–627. 60 indexed citations
7.
Su, Wei‐Wen, et al.. (2013). The Cost Effectiveness of BG-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada. Value in Health. 16(7). A623–A623. 3 indexed citations
8.
9.
Manos, M. Michele, Jeanne Darbinian, Jaime Rubin, et al.. (2013). The Effect of Hepatitis C Treatment Response on Medical Costs: A Longitudinal Analysis in an Integrated Care Setting. Journal of Managed Care Pharmacy. 19(6). 438–447. 40 indexed citations
10.
11.
Walker, A., et al.. (2012). PND1 A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients With Relapsing-Remitting Multiple Sclerosis. Value in Health. 15(4). A140–A141. 1 indexed citations
12.
Menzin, Joseph, Leigh Ann White, Christine Nichols, & Baris Deniz. (2012). The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective. BMC Health Services Research. 12(1). 459–459. 26 indexed citations
13.
Tomaszewski, Krzysztof A., et al.. (2012). Comparison of Current US Risk Strategy to Screen for Hepatitis C Virus With a Hypothetical Targeted Birth Cohort Strategy. American Journal of Public Health. 102(11). e101–e106. 15 indexed citations
14.
McAdam‐Marx, Carrie, Lisa J. McGarry, Christopher A. Hane, et al.. (2011). All-Cause and Incremental Per Patient Per Year Cost Associated with Chronic Hepatitis C Virus and Associated Liver Complications in the United States: A Managed Care Perspective. Journal of Managed Care Pharmacy. 17(7). 531–546. 147 indexed citations
15.
Deniz, Baris, Gareth J. Morgan, Steve Schey, et al.. (2008). Economic Evaluation of Lenalidomide Combined with Dexamethasone for the Treatment of Multiple Myeloma in the UK. Blood. 112(11). 2400–2400. 4 indexed citations
16.
17.
Deniz, Baris, Mark T. Drayson, Gareth J. Morgan, et al.. (2008). Modeling overall survival in the event of patient cross-over from dexamethasone to lenalidomide in phase III multiple myeloma trials. 1 indexed citations
18.
19.
Deniz, Baris, et al.. (2008). PSY14 ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR MULTIPLE MYELOMA IN SCOTLAND IN PATIENTSWHO HAVE RECEIVED ONE PRIOR THERAPY. Value in Health. 11(3). A156–A156. 2 indexed citations
20.
Ece, Aydın, et al.. (1988). Once daily ceftriaxone for meningococcemia and meningococcal meningitis. The Pediatric Infectious Disease Journal. 7(10). 711–713. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Farhad Peerani Breakdown of academic impact, for papers by Angie Price Breakdown of academic impact, for papers by Hesham Elghazaly Breakdown of academic impact, for papers by Jean‐Charles Ryff Breakdown of academic impact, for papers by V. Iodice Breakdown of academic impact, for papers by Carmen Monica Preda Breakdown of academic impact, for papers by G Bardazzi Breakdown of academic impact, for papers by M.-S. Dai Breakdown of academic impact, for papers by Lotte C. Dinesen Breakdown of academic impact, for papers by Faleh Z. Al-Faleh
Rankless by CCL
2026